About bone biologics corp - BBLG
Bone Biologics Corp. operates as a medical device company. engages in the research and development of bone regeneration in spinal fusion. Its product is Nell-1, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. Its platform technology has application in delivering improved outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company was founded by Eric Kang Ting, Chia Soo and Benjamin Wu in 2004 and is headquartered in Burlington, MA.
BBLG At a Glance
Bone Biologics Corp.
2 Burlington Woods Drive
Burlington, Massachusetts 01803
| Phone | 1-781-552-4452 | Revenue | 0.00 | |
| Industry | Medical Specialties | Net Income | -4,112,420.00 | |
| Sector | Health Technology | Employees | 2 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
BBLG Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.797 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.45 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
BBLG Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,056,210.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
BBLG Liquidity
| Current Ratio | 10.223 |
| Quick Ratio | 10.223 |
| Cash Ratio | 8.803 |
BBLG Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -108.234 |
| Return on Equity | -128.714 |
| Return on Total Capital | -118.049 |
| Return on Invested Capital | -128.714 |
BBLG Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |